Medipost Co Ltd announced that it has received KRW 10.10 billion in funding from Seoul Investments & Susung & E-um PEF.
October 13, 2014 at 05:00 am
Share
Medipost Co Ltd (KOSDAQ:A078160) announced a private placement of sixth unregistered/unsecured private convertible bonds for gross proceeds of KRW 10,100,000,000 with new investor, Seoul Investments & Susung & E-um PEF on October 13, 2014. The bonds will mature on October 14, 2019. The bonds bear an interest at a fixed rate of 2.25% per annum and yield to maturity of 3.5% per annum. The bonds are 100% convertible into common shares of the company at a fixed conversion price of KRW 57,751 per share. The conversion period is from October 14, 2015 to September 14, 2019. The bonds have lump-sum redemption of principal on maturity date.
On October 13, 2014, Medipost Co Ltd closed the transaction.
MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
MEDIPOST CO., LTD. 
